Which peptides are studied for weight and metabolic conditions?
Short answer
32 profiles here are grouped under “Metabolic and weight”: 15 FDA-approved, 1 approval reported abroad, 11 in clinical trials and 5 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 15
FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.4,5
Is dulaglutide FDA-approved? · Dulaglutide vs Semaglutide · Dulaglutide vs Tirzepatide
FDA-approved as Victoza, Saxenda and generic versions18,19,20,21
FDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.18,19,20,21
Is liraglutide FDA-approved? · Liraglutide vs Semaglutide · Liraglutide vs Tirzepatide
Metreleptin
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides
Orforglipron
Not a peptide: a small molecule often looked up alongside peptides
FDA-approved as Foundayo for weight reduction in adults27,28
FDA-approved. Drugs@FDA lists Foundayo with an original approval date of April 1, 2026. The label has a boxed warning about the risk of thyroid C-cell tumors.27,28
Is orforglipron FDA-approved? · Orforglipron vs Semaglutide · Orforglipron vs Tirzepatide
FDA-approved as Ozempic, Rybelsus and Wegovy31,32,33,34
FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.31,32,33,34
Is semaglutide FDA-approved? · Semaglutide vs Tirzepatide · Semaglutide vs Retatrutide
FDA-approved as Egrifta for HIV-associated abdominal fat37,38
FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.37,38
Is tesamorelin FDA-approved? · AOD-9604 vs Tesamorelin · Sermorelin vs Tesamorelin
FDA-approved as Mounjaro and Zepbound39,40,41
FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.39,40,41
Is tirzepatide FDA-approved? · Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide
Approval reported abroad 1
In clinical trials 11
In clinical trials; not FDA-approved44,56,57
Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.44
Is cagrilintide FDA-approved? · Cagrilintide vs Semaglutide · Pramlintide vs Cagrilintide
In clinical trials; not FDA-approved60,61,62
Not FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.60,61
Is efpeglenatide FDA-approved? · Efpeglenatide vs Semaglutide
In clinical trials; not FDA-approved65,66,67
Not FDA-approved. Amgen has registered Phase 3 trials on ClinicalTrials.gov, including MARITIME-1 and MARITIME-CV.66,67
Is maridebart cafraglutide FDA-approved? · Maridebart cafraglutide vs Tirzepatide
In clinical trials; not FDA-approved68,69,70
Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.69,70,71
Is petrelintide FDA-approved? · Petrelintide vs Cagrilintide
In clinical trials; not FDA-approved44,72,73
Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.44
Is retatrutide FDA-approved? · Tirzepatide vs Retatrutide · Semaglutide vs Retatrutide
In clinical trials; not FDA-approved44,74,75
Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.44
Is survodutide FDA-approved? · Survodutide vs Retatrutide · Survodutide vs Tirzepatide
Not FDA-approved 5
5-Amino-1MQ
Not a peptide: a small molecule often looked up alongside peptides
Not FDA-approved; FDA advised against adding it to the compounding list62,79,80
Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.62,79
Is AOD-9604 FDA-approved? · AOD-9604 vs Semaglutide · AOD-9604 vs Tesamorelin
Not an FDA-approved drug81
Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.81,82,83
SLU-PP-332
Not a peptide: a small molecule often looked up alongside peptides
Tesofensine
Not a peptide: a small molecule often looked up alongside peptides
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 5Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Exenatide injection · SPL version 17 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 7Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 8Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 9Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 10Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 11GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 12Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 13Drugs@FDA application NDA210134 · original submission status AP · 2019-07-24 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 14Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 15LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 16Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 17Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 18Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 19Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 20Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 21Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 22Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 23ADLYXIN, revised November 2024: U.S. prescribing information ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 24SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 25Drugs@FDA: MYALEPT (metreleptin), application 125390 · original approval February 24, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 26MYALEPT (metreleptin) for injection · SPL version 18 · published 2025-03-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 27Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 28FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 29SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 30Drugs@FDA application NDA021332 · original submission status AP · 2005-03-16 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 31WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 32Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 33Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 34Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 35IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 36Drugs@FDA application NDA213793 · original submission status AP · 2020-11-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 37EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 38Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 39ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 40Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 41Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 42June 27, 2025 government report of Chinese approval for mazdutide weight management ↗
Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026
- 43December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗
Suzhou Municipal Government · Official source · Source checked September 15, 2026
- 44FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 45Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 46Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗
The Lancet · Official source · Source checked November 14, 2026
- 47ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 48ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 49ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 50ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 51ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 52ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 53Avexitide acetate substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 54PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026
- 55Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗
Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026
- 56Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 57ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 58Cotadutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 59Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗
Diabetes Care · Official source · Source checked November 15, 2026
- 60Efpeglenatide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 61ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 62Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 63Eloralintide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 64Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗
The Lancet · Official source · Source checked November 15, 2026
- 65Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 66ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 67ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78 ↗
ClinicalTrials.gov · Official source · Source checked August 13, 2026
- 68Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 69ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 70ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 71ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 72Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 73ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 74BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 75ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 76Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗
Obesity · Official source · Source checked November 16, 2026
- 77ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 785-Amino-1-methylquinolinium substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 79FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 80December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 81FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 82Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 83HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 84SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 85Tesofensine substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026